Antiretroviral therapy (ART) has evolved considerably over the past three decades. With many antiretroviral (ARV) drugs, combinations and classes available, health care providers have multiple choices regarding ARV therapy. In recent years, significant progress has been made in the treatment of HIV, but many clinicians who manage patients infected with HIV are not aware of the full range of complex and emerging treatment options available or how to apply them to various patient scenarios. Due to the rapidly changing landscape in HIV management, this situation can significantly affect the treatment of patients with HIV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality, and treatment costs.
The HIV Virtual Patient program is an interactive, case-based program featuring real-world case scenarios discussed by HIV thought leaders. Participants will be asked to assess and treat a variety of HIV-positive and HIV-negative patient types with the direction and consultation of HIV thought leaders. This program provides important information that can be directly applied to clinical practice, thereby increasing the delivery of optimal care to patients with HIV infection in the United States.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, participants should be better able to:
Release Date: May 9, 2017
Expiration Date: May 9, 2018
Estimated time to complete each Virtual Patient Case: 30-60 minutes
Media: Internet
| Richard A. Elion, MD Associate Professor of Clinical Medicine George Washington University Medical Center Washington, DC |
Ian Frank, MD Professor of Medicine Director, Clinical Therapeutics Program Penn Center for AIDS Research Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania |
| Wilbert Jordan, MD Medical Director Charles Drew Medical Center Los Angeles, California |
Paul Sax, MD, MD Clinical Director Division of Infectious Diseases Brigham and Women's Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts |
| Renslow Sherer, MD Professor of Medicine, Section of Infectious Diseases and Global Health University of Chicago Chicago, Illinois |
Kathleen E. Squires, MD W Paul and Ida H Havens Professor of Infectious Diseases Director, Division of Infectious Diseases Sidney Kimmel Medical College of Thomas Jefferson University Medical Director, Infectious Diseases and Population Management Jefferson Health System Philadelphia, Pennsylvania |
| Pablo Tebas, MD Professor of Medicine Hospital of the University of Pennsylvania Director, Adult AIDS Clinical Trials Unit (ACTU) Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania |
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Richard Elion, MD
Wilbert Jordan, MD
Renslow Sherer, MD
Kathleen Squires, MD
Pablo Tebas, MD
David Wohl, MD
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP have nothing to disclose.
There are no fees for participating and receiving CME credit for this activity. During the period, May 9, 2017 through May 9, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12282. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
